BeiGene (HKG:6160, SHA:688235) recorded a net income of $1.3 million in the first quarter, compared with a net loss of $251.2 million in the year-ago period, a Wednesday Hong Kong bourse filing said.

The company did not make any earnings per share in the three months, while it had incurred a loss per share of $0.19 in the corresponding period of the last year.

Revenue for the pharmaceutical company rose 49% to $1.12 billion in the quarter from $751.7 million a year prior, driven primarily by higher product sales under the BRUKINSA brand in the US and Europe.